MEMORIAL HOSPITAL FOR CANCER AND ALL
1. Target Overview & Investment Thesis
MEMORIAL HOSPITAL FOR CANCER AND ALL is a 514-bed large academic medical center in NEW YORK, NY with $4.34B in net patient revenue and a -32.5% operating margin. The hospital serves a payer mix of 35.7% Medicare, 2.1% Medicaid, and 62.2% commercial.
Thesis: Undervalued. Our ML models identify $319.7M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -32.5% to -25.1% (+736bps).
| Net Revenue HCRIS | $4.34B |
| Current EBITDA COMPUTED | $-1.41B |
| Operating Margin COMPUTED | -32.5% |
| Occupancy HCRIS | 90.7% |
| Revenue / Bed COMPUTED | $8.5M |
| Net-to-Gross HCRIS | 37.3% |
| Distress Probability ML | 31.1% |
2. Market Context & Competitive Position
NY has 196 Medicare-certified hospitals with a median operating margin of -17.5%. The target's margin of -32.5% places it below the state median. Among 56 size-comparable peers (257-1028 beds), the median margin is -17.6%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (257-1028), prioritizing same-state peers. 56 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| MEMORIAL HOSPITAL FOR CANCER A (Target) | NY | 514 | $4.34B | -32.5% |
| STRONG MEMORIAL HOSPITAL | NY | 749 | $3.31B | 5.2% |
| NORTH SHORE UNIVERSITY HOSPITA | NY | 782 | $2.27B | -50.0% |
| STONY BROOK UNIVERSITY HOSPITA | NY | 725 | $1.90B | -4.9% |
| WESTCHESTER MEDICAL CENTER | NY | 696 | $1.63B | 2.6% |
| KALEIDA HEALTH | NY | 954 | $1.38B | -8.8% |
| UNIVERSITY HOSPITAL AT SYRACUS | NY | 625 | $1.33B | -17.2% |
| LENOX HILL HOSPITAL | NY | 415 | $1.32B | -35.1% |
| BELLEVUE HOSPITAL CENTER | NY | 527 | $1.31B | -17.6% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $319.7M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $91.2M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $86.9M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $86.0M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $52.9M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $2.8M | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-1.41B |
| + RCM Uplift | +$319.7M |
| Pro Forma EBITDA | $-1.09B |
| Current Margin | -32.5% |
| Pro Forma Margin | -25.1% |
| WC Released (1x) | $166.6M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-2.17B | $-6.11B | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-2.17B | $-7.42B | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-1.95B | $-7.07B | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-1.95B | $-8.29B | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-2.39B | $-7.00B | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-2.39B | $-8.48B | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 56 hospitals with 257-1028 beds
- Same-state prioritization (n=57)
- Comp margins: P25=-26.5% / P50=-17.6% / P75=-8.9%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.